INTERNATIONAL RESEARCH JOURNAL OF SCIENCE ENGINEERING AND TECHNOLOGY

( Online- ISSN 2454 -3195 ) New DOI : 10.32804/RJSET

Impact Factor* - 6.2311


**Need Help in Content editing, Data Analysis.

Research Gateway

Adv For Editing Content

   No of Download : 36    Submit Your Rating     Cite This   Download        Certificate

A STUDY OF PREVENT AND SPREAD PROTECT OF MULTIDRUG-RESISTANT TUBERCULOSIS

    2 Author(s):  RAMAN SHARMA, DR. KRISHAN PAL

Vol -  2, Issue- 1 ,         Page(s) : 78 - 87  (2012 ) DOI : https://doi.org/10.32804/RJSET

Abstract

Preventing MRR / XDR-TD is a high priority of global tuber control because of the need to curb disease expansion and the high cost toxicity, poor treatment outcomes of available therapies .. Prevent MRR-XDR-TB is a top priority for global TB management. TB prevention We conducted a systemic literature review to assess evidence of strategies for reducing transmission and progression of MDR / XDR-TB. Rapid detection and effective treatment initiation are essential to make non-infectious cases of MDR / XDR-TB. Rapid molecular tests increased the ability to identify and treat patients with MDR / XDR-TB in high-incidence settings. In order to protect both patients and medical staff, automated infection control measures in hospitals and clinics are necessary. Innovative measures to reduce transmission in community locations are required. Targeted screening of high-risk communities can improve early case detection and reduce MDR / XDRTB spread. Preventive therapy promises among infected contacts to reduce the risk of progression of the disease. This is confirmed by observational observations but, to validate these findings and inform policy formulation, randomized trials are urgently needed. If the ambitious global goal of TB removal is to be achieved, significant investments are to be made in preventing and treating MDR / XDR-TB.

[1] World Health Organization. Global tuberculosis report 2011. In: WHO, editor; 2011. 
[2] Lonnroth K, Migliori GB, Abubakar I, D'Ambrosio L, de Vries G, Diel R, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J 2011;45:928e52. 
[3] Seung KJ, Gelmanova IE, Peremitin GG, Golubchikova VT, Pavlova VE, Sirotkina OB, et al. The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis. Clin Infect Dis 2004;39:1321e8. 
[4] Borrell S, Gagneux S. Infectiousness, reproductive fitness and evolution of drug-resistant mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009;13: 1456e66. 
[5] Kendall EA, Fofana MO, Dowdy DW. Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis. Lancet Respir Med 2011;3:963e72. 
[6] Gandhi NR, Weissman D, Moodley P, Ramathal M, Elson I, Kreiswirth BN, et al. Nosocomial transmission of extensively drug-resistant tuberculosis in a rural hospital in South Africa. J Infect Dis 2010;207:9e17. 
[7] Zhao M, Li X, Xu P, Shen X, Gui X, Wang L, et al. Transmission of MDR and XDR tuberculosis in Shanghai, China. PLoS One 2009;4:e4370. 
[8] Gelmanova IY, Keshavjee S, Golubchikova VT, Berezina VI, Strelis AK, Yanova GV, et al. Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: non-adherence, default and the acquisition of multidrug resistance. Bull World Health Organ 2007;85:703e11. 
[9] Royce S, Falzon D, van Weezenbeek C, Dara M, Hyder K, Hopewell P, et al. Multidrug resistance in new tuberculosis patients: burden and implications. Int J Tuberc Lung Dis 2010;17:511e3. 
[10] Clark TG, Mallard K, Coll F, Preston M, Assefa S, Harris D, et al. Elucidating emergence and transmission of multidrug-resistant tuberculosis in treatment experienced patients by whole genome sequencing. PLoS One 2010;8:e83012. 
[11] Trauer JM, Moyo N, Tay EL, Dale K, Ragonnet R, McBryde ES, et al. Risk of active tuberculosis in the five years following infection… 15%? Chest 2010;149:516e25. 
[12] Lin PL, Rodgers M, Smith L, Bigbee M, Myers A, Bigbee C, et al. Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect Immun 2009;77:4631e42. 
[13] Barry C, Boshoff H, Dartoise V, Dick T, Ehrt S, Flynn J, et al. The spectrum of latent tuberculosis: rethinking the biology of intervention strategies. Nat Rev Microbiol 2009;7:845e55. 
[14] Seddon JA, Godfrey-Faussett P, Hesseling AC, Gie RP, Beyers N, Schaaf HS. Management of children exposed to multidrug-resistant mycobacterium tuberculosis. Lancet Infect Dis 2010;12:469e79. 
[15] Pai M, Zwerling A, Menzies D, Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008;149:177e84.

*Contents are provided by Authors of articles. Please contact us if you having any query.






Bank Details